Latest news with #SapioSciences
Yahoo
27-05-2025
- Business
- Yahoo
Sapio Sciences Appoints Gordon McCall as Chief Operating Officer to Drive Global Operational Excellence
New role underscores Sapio's commitment to operational excellence and elevating customer delivery across global markets BALTIMORE, May 27, 2025--(BUSINESS WIRE)--Sapio Sciences, the science-aware™ lab informatics platform, today announced the promotion of Gordon McCall to Chief Operating Officer (COO). McCall has served as the company's Chief Financial Officer (CFO) since 2022 and brings a proven track record of leadership, strategic execution, and operational acumen. As COO, McCall will oversee the implementation of Sapio's day-to-day operations, including leading global customer delivery teams, managing customer relationships, and overseeing key operational functions. He will serve as the bridge between Sapio's strategic vision and its operational execution, with a mandate to drive excellence in customer delivery and customer satisfaction. Kevin Cramer, CEO and CTO at Sapio Sciences, commented: "Gordon has consistently demonstrated a deep understanding of what it takes to build and scale a customer-centric organization. Through both his financial leadership and ownership of operational responsibilities, Gordon was the natural choice to lead the next chapter of Sapio's success." Gordon McCall, COO at Sapio Sciences, added: "The strength of Sapio lies in its people, its mission, and its relentless focus on delivering real impact for customers in the biopharma community, and I am excited to help grow and support Sapio's business and our commitment to operational excellence." Sapio Sciences is focused on strengthening customer delivery through coordinated improvements in technology, people, and processes. The company is investing in tools to enhance resource planning and operational visibility, supporting its teams with the training and structure needed to scale delivery effectively, and refining internal workflows to drive greater consistency, faster time to value, and better project outcomes. These efforts are designed to help Sapio scale with confidence and continue meeting the evolving needs of its global customer base. About Sapio Sciences At Sapio Sciences, our mission is to improve lives by accelerating discovery and diagnostics. Our cloud-based solutions—LIMS, ELN, and Scientific Data Cloud—are unified on a flexible, configurable, and AI-native informatics platform, streamlining complex workflows, unifying scientific data, and enabling faster, smarter decisions across biopharma research and development, clinical diagnostics, and manufacturing. Trusted by global leaders and innovators worldwide, we support a wide range of best-in-class applications, from NGS and bioanalysis to bioprocessing, stability studies, histopathology, antibody discovery, and in vivo studies. Discover how Sapio Sciences can revolutionize your lab operations at and follow us on LinkedIn. View source version on Contacts Media contacts: Zyme Communications Anna BakewellTel: +44 (0)7801 098 242Email: Tim BrookHead of PR, Sapio SciencesTel: +44 (0)7760 766 213Email: press@ Sign in to access your portfolio
Yahoo
29-04-2025
- Business
- Yahoo
Sapio Sciences Introduces Biorepository Management Solution in Sapio Release 25.4
Latest release of Sapio Platform streamlines sample workflows and delivers centralized, compliant biospecimen management BALTIMORE, April 29, 2025--(BUSINESS WIRE)--Sapio Sciences, the science-aware™ lab informatics platform, today announced Sapio Release 25.4, introducing a new Biorepository Management solution, enhanced sample management capabilities, and platform-wide enhancements designed to streamline lab operations and support high-throughput research environments. New Biorepository Management Solution The new Sapio Biorepository solution gives labs centralized, flexible management of biospecimens across multiple sites. Designed for highly regulated environments, including biopharma R&D, clinical trials, biobanks, genomics, and personalized medicine, the solution enhances visibility, traceability, and coordination across the entire sample lifecycle. Sapio Biorepository Management supports advanced workflows, including aliquoting, pooling, slide preparation, and barcode-based tracking, while enabling labs to manage sample browsing, registration, storage, requests, sample preparation, and shipping from a centralized dashboard. The solution includes barcode tracking, electronic signature support, automated discrepancy resolution, and complete audit trails to ensure regulatory-grade compliance and traceability. From a central dashboard, users can monitor and manage biorepository activities, initiate and receive shipments, and oversee sample status across facilities. Role-based access controls allow organizations to assign specific permissions by site or study. Sapio Biorepository Management offers no/low-code configurability, operates as a standalone solution, and can easily be integrated with Sapio's LIMS, ELN, and Scientific Data Cloud and other informatics providers. Kevin Cramer, CEO and CTO of Sapio Sciences, commented: "Biorepository and sample logistics are becoming increasingly complex, especially for organizations managing large collections across multiple sites. Our new biorepository solution gives labs the automation, visibility, and compliance tools to manage this growing complexity with greater confidence. It's important to do this at scale, supporting tens of millions of samples, and we have proved that the Sapio solution is up for the task." Kevin continued: "Sapio's mission has always been to simplify science. With every release, we're deepening our commitment to helping researchers work more efficiently, collaborate more effectively, and accelerate discovery." Modernized Sample Management Sapio Release 25.4 also introduces major updates to sample management functionality, enabling researchers to register, receive, and request samples independently in a more user-friendly interface. Users can easily initiate these actions and register material samples like reagents and compounds, but also non-material samples including blood and tissue. Samples can be manually added or imported in bulk from a spreadsheet, and Sapio's best-in-class API also enables sample activities through plugins or webhooks. Additional Highlights in Sapio Release 25.4: Storage Enhancements: End users can now create storage units directly under defined locations. Molecular Biology Tools: New Codon Optimization and Gibson Assembly Wizards. Chemistry: Compound search filters can be saved and exported to SDF format. Study Design: AI-assisted study plan generation and document-based planning. Quick Search Improvements: More intuitive multi-type filtering and enhanced search performance. Charting and Rules Updates: Manual chart refresh options and expanded rule configuration support. Major scalability improvements in several key product areas About Sapio Sciences At Sapio Sciences, our mission is to improve lives by accelerating the entire drug lifecycle. Our cloud-based solutions—LIMS, ELN, and Scientific Data Cloud— are unified on a flexible, configurable, and AI-native informatics platform, streamlining complex workflows, unifying scientific data, and enabling faster, smarter decisions across biopharma research and development, clinical diagnostics, and manufacturing. Trusted by global leaders and innovators worldwide, we support many best-in-class applications, from NGS and bioanalysis to bioprocessing, stability studies, histopathology, antibody discovery, and in vivo studies. Discover how Sapio Sciences can revolutionize your lab operations at and follow us on LinkedIn. View source version on Contacts Media contacts: Zyme Communications Anna BakewellTel: +44 (0)7801 098 242Email: Tim BrookHead of PR, Sapio SciencesTel: +44 (0)7760 766 213Email: press@
Business Wire
29-04-2025
- Business
- Business Wire
Sapio Sciences Introduces Biorepository Management Solution in Sapio Release 25.4
BALTIMORE--(BUSINESS WIRE)-- Sapio Sciences, the science-aware™ lab informatics platform, today announced Sapio Release 25.4, introducing a new Biorepository Management solution, enhanced sample management capabilities, and platform-wide enhancements designed to streamline lab operations and support high-throughput research environments. New Biorepository Management Solution The new Sapio Biorepository solution gives labs centralized, flexible management of biospecimens across multiple sites. Designed for highly regulated environments, including biopharma R&D, clinical trials, biobanks, genomics, and personalized medicine, the solution enhances visibility, traceability, and coordination across the entire sample lifecycle. Sapio Biorepository Management supports advanced workflows, including aliquoting, pooling, slide preparation, and barcode-based tracking, while enabling labs to manage sample browsing, registration, storage, requests, sample preparation, and shipping from a centralized dashboard. The solution includes barcode tracking, electronic signature support, automated discrepancy resolution, and complete audit trails to ensure regulatory-grade compliance and traceability. From a central dashboard, users can monitor and manage biorepository activities, initiate and receive shipments, and oversee sample status across facilities. Role-based access controls allow organizations to assign specific permissions by site or study. Sapio Biorepository Management offers no/low-code configurability, operates as a standalone solution, and can easily be integrated with Sapio's LIMS, ELN, and Scientific Data Cloud and other informatics providers. Kevin Cramer, CEO and CTO of Sapio Sciences, commented: 'Biorepository and sample logistics are becoming increasingly complex, especially for organizations managing large collections across multiple sites. Our new biorepository solution gives labs the automation, visibility, and compliance tools to manage this growing complexity with greater confidence. It's important to do this at scale, supporting tens of millions of samples, and we have proved that the Sapio solution is up for the task.' Kevin continued: 'Sapio's mission has always been to simplify science. With every release, we're deepening our commitment to helping researchers work more efficiently, collaborate more effectively, and accelerate discovery.' Modernized Sample Management Sapio Release 25.4 also introduces major updates to sample management functionality, enabling researchers to register, receive, and request samples independently in a more user-friendly interface. Users can easily initiate these actions and register material samples like reagents and compounds, but also non-material samples including blood and tissue. Samples can be manually added or imported in bulk from a spreadsheet, and Sapio's best-in-class API also enables sample activities through plugins or webhooks. Additional Highlights in Sapio Release 25.4: Storage Enhancements: End users can now create storage units directly under defined locations. Molecular Biology Tools: New Codon Optimization and Gibson Assembly Wizards. Chemistry: Compound search filters can be saved and exported to SDF format. Study Design: AI-assisted study plan generation and document-based planning. Quick Search Improvements: More intuitive multi-type filtering and enhanced search performance. Charting and Rules Updates: Manual chart refresh options and expanded rule configuration support. Major scalability improvements in several key product areas About Sapio Sciences At Sapio Sciences, our mission is to improve lives by accelerating the entire drug lifecycle. Our cloud-based solutions— LIMS, ELN, and Scientific Data Cloud — are unified on a flexible, configurable, and AI-native informatics platform, streamlining complex workflows, unifying scientific data, and enabling faster, smarter decisions across biopharma research and development, clinical diagnostics, and manufacturing. Trusted by global leaders and innovators worldwide, we support many best-in-class applications, from NGS and bioanalysis to bioprocessing, stability studies, histopathology, antibody discovery, and in vivo studies. Discover how Sapio Sciences can revolutionize your lab operations at and follow us on LinkedIn.
Yahoo
19-03-2025
- Science
- Yahoo
Sapio Sciences Makes AI-Native Drug Discovery Seamless with NVIDIA BioNeMo
Integration of the NVIDIA BioNeMo platform enhances AI capabilities across the drug discovery lifecycle BALTIMORE, March 19, 2025--(BUSINESS WIRE)--Sapio Sciences, the science-aware™ lab informatics platform, today announced the integration of the NVIDIA BioNeMo platform into the Sapio Lab Informatics Platform. This integration brings AI-driven computational drug discovery directly into Sapio ELN (Electronic Lab Notebook), helping to streamline workflows and improve decision-making in drug discovery. With the BioNeMo platform, researchers can accelerate drug discovery by leveraging science-specific AI frameworks, pre-trained models, and generative AI tools to streamline the identification of potential drug candidates and improve target selection accuracy. NVIDIA BioNeMo provides scientists with a framework for training and deploying large biomolecular language models at supercomputing scale. The integration of BioNeMo into the Sapio Platform provides scientists with embedded in silico tools, enabling them to, for example, generate novel candidate molecules early in the research process and test their docking with a target protein. With AI-driven molecular simulations available within a single, unified workflow, researchers can streamline their processes, enhance innovation, and accelerate the transition from discovery to development. Within Sapio ELN, researchers can access BioNeMo NIM microservices to rapidly identify and optimize drug candidates using AI-driven molecular modeling, including AlphaFold2 NIM for predicting accurate 3D protein structures; MoIMIM NIM to enable the design and optimization of small molecules; and DiffDock NIM, an AI-powered docking model developed by MIT. These models provide scientists with easy access to AI-driven tools without extensive setup, ensuring faster, more efficient research workflows. Kevin Cramer, Founder, CEO & CTO at Sapio Sciences, commented: "AI innovation is advancing rapidly, but scientists are often forced to navigate fragmented tools with complex interfaces, slowing down research. Our integration of NVIDIA's powerful AI-driven tools directly into the Sapio Platform enables researchers to apply AI seamlessly into their experiments. Through this work, we are removing inefficiencies and equipping scientists with the tools to rapidly generate, analyze, and visualize both chemical and biological results." Kevin continued: "We are working with NVIDIA to equip scientists and researchers with the most advanced AI tools to drive innovation in life sciences. This collaboration is a major step toward making AI an integral part of the drug discovery process, helping researchers make faster, data-driven decisions and improve research outcomes." Anthony Costa, Director, Digital Biology at NVIDIA, commented: "Integrating BioNeMo into Sapio's AI-driven research platform gives scientists access to advanced generative AI models for drug discovery. With AlphaFold2, MoIMIM, and DiffDock NIMs, researchers can predict, optimize, and validate drug candidates with greater speed and accuracy. This work underscores AI's growing role in transforming pharmaceutical research and accelerating the path to breakthrough treatments." Integrating NVIDIA technologies into the Sapio Platform is one of the many ways Sapio Sciences is helping to improve and accelerate biopharma discovery, clinical diagnostics, and drug manufacturing. Find out more about the Sapio/NVIDIA integration here. About Sapio Sciences At Sapio Sciences, our mission is to improve lives by accelerating the entire drug lifecycle. Our cloud-based solutions—LIMS, ELN, and Scientific Data Management—are unified on a flexible, configurable, and AI-powered informatics platform, streamlining complex workflows, unifying scientific data, and enabling faster, smarter decisions across biopharma research and development, clinical diagnostics, and manufacturing. Trusted by global leaders and innovators worldwide, we support a wide range of best-in-class applications, from NGS and bioanalysis to bioprocessing, stability studies, histopathology, antibody discovery, and in vivo studies. Discover how Sapio Sciences can revolutionize your lab operations at and follow us on LinkedIn. View source version on Contacts Media contacts: Zyme Communications Anna BakewellTel: +44 (0)7801 098 242Email: Tim BrookHead of PR, Sapio SciencesTel: +44 (0)7760 766 213Email: press@
Yahoo
28-01-2025
- Business
- Yahoo
Schrödinger Selects Sapio Sciences to Enhance In Silico Drug Discovery from Plasmid to Structure
Configurable informatics platform improves lab efficiency, data tracking, and resource management from plasmid to structure BALTIMORE, January 28, 2025--(BUSINESS WIRE)--Sapio Sciences, the science-aware™ lab informatics platform, today announced that Schrödinger, a global leader in computational chemistry, has adopted the Sapio Platform to improve data management, enhance lab efficiency, and accelerate the discovery of novel molecules. By deploying Sapio's unified informatics platform, including Sapio LIMS and Sapio ELN, Schrödinger is transforming its recently acquired wet lab operations, integrating data, and streamlining workflows. Schrödinger established its internal wet lab after acquiring a contract research organization (CRO) in 2021. However, the lab's reliance on manual, paper-based processes posed significant challenges in scalability, traceability, and operational efficiency. Transitioning to Sapio's no-code informatics platform has provided a scalable, flexible solution that simplifies operations and accelerates scientific progress. Dr. Rajesh Kumar, Senior Director of Drug Discovery at Schrödinger, commented: "Sapio's solution has allowed us to digitize critical lab functions, improve efficiency, and ensure seamless sample traceability across our research and discovery processes. By unifying data and automating workflows, we're able to focus on advancing our research with greater speed and confidence." Since adopting the Sapio Platform, Schrödinger has realized several key benefits, including: Improved visibility across the discovery process: Researchers now have a clear, real-time view of every stage, optimizing resource use and improving overall efficiency. Comprehensive data traceability: Detailed documentation of lab activities simplifies audits, accelerates regulatory filings, and ensures full compliance. Optimized resource allocation: Access to historical data enables better planning, budgeting, and distribution of resources across multiple projects. Long-term knowledge retention: A centralized knowledge base allows scientists to easily retrieve critical data, supporting ongoing and future research initiatives. Mike McCartney, Chief Commercial Officer at Sapio Sciences, commented: "Schrödinger's adoption of the Sapio Platform highlights the increasing demand for configurable informatics solutions that unify complex lab environments. By eliminating data silos and improving lab efficiency, we're enabling Schrödinger to accelerate drug discovery and drive innovation." The full story on the Schrödinger implementation can be found here. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs and is advancing three clinical-stage oncology programs. Founded in 1990, Schrödinger has approximately 900 employees operating from 15 locations globally. To learn more, visit About Sapio Sciences At Sapio Sciences, our mission is to improve lives by accelerating discovery and diagnostics. Our cloud-based solutions—LIMS, ELN, and Scientific Data Management—are unified on a flexible, configurable, and AI-powered informatics platform, streamlining complex workflows, unifying scientific data, and enabling faster, smarter decisions across biopharma research and development, clinical diagnostics, and manufacturing. Trusted by global leaders and innovators worldwide, we support a wide range of best-in-class applications, from NGS genomic sequencing and bioanalysis to bioprocessing, stability studies, histopathology, antibody discovery, and in vivo studies. Discover how Sapio Sciences can revolutionize your lab operations at and follow us on LinkedIn. View source version on Contacts For further information, please contact: Zyme Communications Anna BakewellTel: +44 (0)7801 098 242Email: Tim BrookHead of PR, Sapio SciencesTel: +44 (0)7760 766 213Email: press@
